slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 26,041-26,070
Pages 1,437
Rows per page 30
Arc
26,041-26,070 of 43,093
03
The slide uses a three-column layout to categorize revenue streams: Drug Discovery (yellow), Development Pipeline (orange), and Knowledge Exploration Tools (teal).BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a value-chain style flow from left to right, emphasizing the integration of diverse data types into a central knowledge graph.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
BenevolentAI | Investor Conference Presentation Deck | 22 slidesBenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
Slide 6 of a presentation deck.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
BenevolentAI | Investor Conference Presentation Deck | 22 slidesBenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
08
The slide uses a split-layout with a dark sidebar for strategic context and a white main area for product details.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
20
The table presents normalized operating loss and EPS, excluding specific exceptional items as detailed in the footnotes.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
21
The table reconciles reported operating loss to normalised operating loss by adding back non-recurring restructuring and transaction-related costs.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
22
The slide provides a bridge between operating loss and cash flow, with explanatory notes on the right.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Financials1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to illustrate the binding mechanism.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
11
The chart uses a dot plot format to show the occurrence of specific GI symptoms over a 29-day study period across different subjects.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
The diagram illustrates a dose escalation study design with combination therapy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
13
Data cut date: 15Nov23BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
Data cut date: 15Nov23. Pt = Platinum.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
Data table showing safety profile by dose cohort.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
16
The slide highlights a low incidence of immune-related adverse events (2 out of 18 patients).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
This is a classic 'spider plot' or 'swimmer plot' variant used in oncology clinical trials to visualize individual patient tumor burden changes over time.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Before-after medical imaging comparison.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
The slide uses a before-and-after medical imaging comparison to demonstrate drug efficacy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The table tracks 3 patients across different cancer types, detailing their age, prior treatments, adverse events, dose-limiting toxicities (DLT), cycles completed, response, and current disposition.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
24
The slide uses a 2x2 grid of metrics to frame the problem/opportunity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
25
Includes comparative context to historical studies (pazopanib, pembrolizumab).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
26
Includes decision criteria for 'Go'/'No Go' based on clinical response and PFS rates.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
27
Includes specific adverse event data and clinical observations.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
28
Details specific patient enrollment numbers (~80 total, ~60 for primary analysis) and dosing randomization criteria.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
29
The slide uses a grid of metrics to define the addressable market and the clinical problem (progression after 1L).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
30
The slide presents clinical evidence linking AXL expression to poor patient outcomes in two different cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
54
The slide uses a simple 2-column table structure to represent a timeline.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Why Now1 hit
55
Uses a Venn-like diagram to connect technology, pipeline, and financial status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Why Now1 hit